Chronic insomnia and poor sleep quality are among the most common ailments that healthcare professionals manage.
Circadin®, prolonged-release melatonin, is indicated for the short term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over. It helps restore the natural sleep rhythm by increasing the body’s own level of this naturally occurring hormone at night.
Until recently, Circadin® was available as a 3 week course of treatment, but it is now approved for longer use in patients with primary insomnia. Following an extension to its current licence, doctors can now prescribe Circadin® for a period of up to 13 weeks, if required.
